Literature DB >> 14600525

Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort.

Stephanie K Brodine1, Monica J Starkey, Richard A Shaffer, Stanley I Ito, Sybil A Tasker, Anthony J Barile, Cindy L Tamminga, Kevin T Stephan, Naomi E Aronson, Susan L Fraser, Mark R Wallace, Scott A Wegner, John R Mascola, Francine E McCutchan.   

Abstract

OBJECTIVE: To describe the demographics, risk behaviors, and HIV-1 subtypes in a large cohort of recently HIV-infected military personnel.
DESIGN: Descriptive, cross-sectional study.
METHODS: US military personnel with recent HIV seroconversion from six medical referral centers were enrolled with a self-administered questionnaire, CD4 cell counts, syphilis and hepatitis B serologies, plasma viral RNA levels, and HIV-1 subtype nucleic acid sequencing.
RESULTS: Between February 1997 and May 2000, 520 patients were enrolled. Most [488 (94.3%)] were infected with HIV-1 subtype B. The most prevalent non-B subtype was a circulating recombinant form (CRF01_AE) [17 (61%)]; however, two pure subtypes (C and D), as well as CRF02_AG, CRF09_cpx and a BE recombinant were identified. The likely area of HIV-1 acquisition was the United States for 70% of the volunteers. At least three non-B subtype infections (two subtype C, one subtype CRF01_AE) were apparently acquired domestically. Risk behaviors and comorbid sexually transmitted diseases were reported during the seroconversion period. Volunteers with non-B subtype HIV infection were more likely to report heterosexual contacts [92% vs. 39%; odds ratio (OR), 10.0], including contacts with commercial sex workers (41% vs. 13%; OR, 4.9). The Roche Amplicor version 1.0 assay was less sensitive for non-B subtype infections than the Roche Amplicor version 1.5 assay.
CONCLUSION: There is a high prevalence and diversity of non-B HIV subtypes in this large cohort. Efficient diagnosis of acute primary HIV-1 infection was identified as a goal for prevention programs. Modifiable risk behaviors and target populations for intervention were identified.

Entities:  

Mesh:

Year:  2003        PMID: 14600525     DOI: 10.1097/00002030-200311210-00016

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  27 in total

1.  Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters.

Authors:  Helen M Chun; Mollie P Roediger; Katherine Huppler Hullsiek; Chloe L Thio; Brian K Agan; William P Bradley; Sheila A Peel; Linda L Jagodzinski; Amy C Weintrob; Anuradha Ganesan; Glenn Wortmann; Nancy F Crum-Cianflone; Jason D Maguire; Michael L Landrum
Journal:  J Infect Dis       Date:  2011-12-05       Impact factor: 5.226

2.  Condom use following a pilot test of the Popular Opinion Leader intervention in the Barbados Defence Force.

Authors:  Michael P Anastario; Julia Dabreo; Jackie Morris; Rachel Hallum-Montes; Gricel Arredondo; Alisha Creel; Lisa Cowan; Helen Chun
Journal:  J Community Health       Date:  2013-02

3.  Brief Report: Racial Comparison of D-Dimer Levels in US Male Military Personnel Before and After HIV Infection and Viral Suppression.

Authors:  Thomas A OʼBryan; Brian K Agan; Russell P Tracy; Matthew S Freiberg; Jason F Okulicz; Kaku So-Armah; Anuradha Ganesan; David Rimland; Tahaniyat Lalani; Robert G Deiss; Edmund C Tramont
Journal:  J Acquir Immune Defic Syndr       Date:  2018-04-15       Impact factor: 3.731

4.  Results of a 25-year longitudinal analysis of the serologic incidence of syphilis in a cohort of HIV-infected patients with unrestricted access to care.

Authors:  Anuradha Ganesan; Ann Fieberg; Brian K Agan; Tahaniyat Lalani; Michael L Landrum; Glenn Wortmann; Nancy F Crum-Cianflone; Alan R Lifson; Grace Macalino
Journal:  Sex Transm Dis       Date:  2012-06       Impact factor: 2.830

5.  Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State.

Authors:  Marine Karchava; Wendy Pulver; Lou Smith; Sean Philpott; Timothy J Sullivan; Judith Wethers; Monica M Parker
Journal:  J Acquir Immune Defic Syndr       Date:  2006-08-15       Impact factor: 3.731

6.  Toward a social theory of sexual risk behavior among men in the Armed Services: understanding the military occupational habitus.

Authors:  Michael P Anastario; Rachel Hallum-Montes; Elfryn Reyes; Russell Manzanero; Helen Chun
Journal:  Cult Med Psychiatry       Date:  2013-12

7.  The timing of hepatitis B virus (HBV) immunization relative to human immunodeficiency virus (HIV) diagnosis and the risk of HBV infection following HIV diagnosis.

Authors:  Michael L Landrum; Katherine Huppler Hullsiek; Helen M Chun; Nancy F Crum-Cianflone; Anuradha Ganesan; Amy C Weintrob; R Vincent Barthel; Robert J O'Connell; Brian K Agan
Journal:  Am J Epidemiol       Date:  2010-11-04       Impact factor: 4.897

8.  Genetic diversity of recently acquired and prevalent HIV, hepatitis B virus, and hepatitis C virus infections in US blood donors.

Authors:  Eric Delwart; Elizabeth Slikas; Susan L Stramer; Hany Kamel; Debra Kessler; David Krysztof; Leslie H Tobler; Danielle M Carrick; Whitney Steele; Deborah Todd; David J Wright; Steven H Kleinman; Michael P Busch
Journal:  J Infect Dis       Date:  2012-01-31       Impact factor: 5.226

9.  Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study.

Authors:  Vincent C Marconi; Greg A Grandits; Amy C Weintrob; Helen Chun; Michael L Landrum; Anuradha Ganesan; Jason F Okulicz; Nancy Crum-Cianflone; Robert J O'Connell; Alan Lifson; Glenn W Wortmann; Brian K Agan
Journal:  AIDS Res Ther       Date:  2010-05-27       Impact factor: 2.250

10.  The effect of human immunodeficiency virus on hepatitis B virus serologic status in co-infected adults.

Authors:  Michael L Landrum; Ann M Fieberg; Helen M Chun; Nancy F Crum-Cianflone; Vincent C Marconi; Amy C Weintrob; Anuradha Ganesan; Robert V Barthel; Glenn Wortmann; Brian K Agan
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.